Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies:final results of two randomised, placebo-controlled trials

Autor: Eron, Jj, Cooper, Da, Steigbigel, Rt, Clotet, B, Gatell, Jm, Kumar, Pn, Rockstroh, Jk, Schechter, M, Markowitz, M, Yeni, P, Loutfy, Mr, Lazzarin, A, Lennox, Jl, Strohmaier, Km, Wan, H, Barnard, Rj, Nguyen, By, Teppler, H, Vullo, Vincenzo, BENCHMRK Study Teams

Publikováno v: Eron, J J, Cooper, D A, Steigbigel, R T, Clotet, B, Gatell, J M, Kumar, P N, Rockstroh, J K, Schechter, M, Markowitz, M, Yeni, P, Loutfy, M R, Lazzarin, A, Lennox, J L, Strohmaier, K M, Wan, H, Barnard, R J, Nguyen, B-Y T, Teppler, H, BENCHMRK Study Teams & Pedersen, C 2013, ' Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies : final results of two randomised, placebo-controlled trials ', The Lancet Infectious Diseases (Portuguese Edition), vol. 13, no. 7, pp. 587-596 . https://doi.org/10.1016/S1473-3099(13)70093-8

Summary Background Two randomised, placebo-controlled trials—BENCHMRK-1 and BENCHMRK-2—investigated the efficacy and safety of raltegravir, an HIV-1 integrase strand-transfer inhibitor. We report final results of BENCHMRK-1 and BENCHMRK-2 combine

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aaa16c338a311ef6d539b5828cebeecb
https://portal.findresearcher.sdu.dk/da/publications/d6e3c5ce-57f2-4108-93c2-3f8bb5182ca3

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

Autor: Cooper, Da, Steigbigel, Rt, Gatell, Jm, Rockstroh, Jk, Katlama, C, Yeni, P, Lazzarin, A, Clotet, B, Kumar, Pn, Eron, Je, Schechter, M, Markowitz, M, Loutfy, Mr, Lennox, Jl, Zhao, J, Chen, J, Ryan, Dm, Rhodes, Rr, Killar, Ja, Gilde, Lr, Strohmaier, Vullo, Vincenzo, Meibohm, Ar, Miller, Md, Hazuda, Dj, Nessly, Ml, Dinubile, Mj, Isaacs, Rd, Teppler, H, Nguyen, By, BENCHMRK STUDY TEAMS

Background: We evaluated the efficacy of raltegravir and the development of viral resistance in two identical trials involving patients who were infected with human immunodeficiency virus type 1 (HIV-1) with triple-class drug resistance and in whom a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acfd904b9414218980a2d17b85e46901
http://hdl.handle.net/11573/85775

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.